Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:CureVac_AG
|
| gptkbp:awards |
various industry awards
|
| gptkbp:businessModel |
collaborative partnerships
licensing agreements research collaborations biopharmaceutical development |
| gptkbp:CEO |
Scott_Wolchko
|
| gptkbp:clinicalTrials |
gptkb:acute_myeloid_leukemia
solid tumors multiple myeloma ongoing clinical studies clinical stage company |
| gptkbp:collaboratesWith |
academic institutions
|
| gptkbp:communityEngagement |
patient advocacy groups
|
| gptkbp:corporateSocialResponsibility |
sustainability efforts
community support initiatives commitment to ethics |
| gptkbp:develops |
immune cell therapies
|
| gptkbp:financialPerformance |
publicly reported financials
|
| gptkbp:focusesOn |
cell therapy
|
| gptkbp:founded |
2014
|
| gptkbp:future_plans |
innovative technologies
|
| gptkbp:futurePlans |
enhancing product offerings
expanding global reach investing in R&D |
| gptkbp:hasPrograms |
diverse experts
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| gptkbp:historicalResearch |
various research projects
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fate Therapeutics
|
| gptkbp:investmentFocus |
various venture capital firms
active investor communications |
| gptkbp:leadership |
experienced professionals
|
| gptkbp:leads |
FT576
FT596 FT819 FT516 FT538 |
| gptkbp:market |
oncology
hematology immunology |
| gptkbp:mission |
transforming cell therapy
|
| gptkbp:partnerships |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:patentCitation |
multiple patents granted
|
| gptkbp:publicAccess |
initial public offering in 2015
|
| gptkbp:regulatoryCompliance |
FDA_approved_therapies
|
| gptkbp:researchFocus |
autoimmune diseases
cancer treatment |
| gptkbp:researchInterest |
numerous publications
|
| gptkbp:stockSymbol |
FATE
|
| gptkbp:strategicGoals |
increasing market presence
expanding product pipeline enhancing partnerships advancing clinical trials |
| gptkbp:technology |
iPSC-derived cell therapies
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:tributaryOf |
multiple product candidates
|
| gptkbp:vision |
improving patient outcomes
|